Aprepitant is associated with improved survival outcomes in early-stage breast cancer, particularly in triple-negative cases, showing significant DDFS and BCSS improvements. The study analyzed 13,811 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results